Management of bone and metabolic effects of androgen deprivation therapy

Androgen deprivation therapy (ADT) is commonly given to men with prostate cancer. Both its benefits as well as its adverse effects are a direct consequence of sex steroid withdrawal. While ADT improves oncologic outcomes in appropriately selected men, it is associated with adverse effects, including accelerated bone loss leading to increased fracture risk, and with metabolically unfavorable body composition changes that predispose to diabetes and may increase cardiovascular risk. In this review, we will describe the pathophysiology behind these ADT-associated adverse effects, and discuss the clinical evidence guiding clinical assessment and management. A proactive approach is important to minimize ADT-associated adverse sequelae, so that the benefit-risk ratio of this treatment is optimized. (C)2018 Elsevier Inc. All rights reserved.

Automated summary

Androgen deprivation therapy (ADT) is commonly used in prostate cancer treatment, with both benefits and adverse effects related to sex steroid withdrawal. Management strategies are crucial in minimizing the adverse effects and optimizing the benefit-risk ratio of this treatment.